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From 1940 to 1986, a total of 798 patients were treated for differentiated 
thyroid carcinoma. One hundred and seventy-two patients died during 
the follow-up period: 42 (24.4%) patients from thyroid cancer, 14 (8.1%) 
from other causes with extensive thyroid cancer present, 75 (43.6%) with 
no thyroid cancer, and 41 (23.8%) with an unknown status of thyroid 
cancer. 
Of  the 42 patients dying due to thyroid cancer, 15 were male and 27, 
female. Mean age at diagnosis was 48.3 -+ 17.7 years with one-third of 
patients age 45 or younger at the time of the initial diagnosis. The primary 
tumors were large ( > 4  cm) and 59.5% of the patients had local invasion 
and/or cervical metastasis. Distant metastases were present in 9 (21.4%) 
patients at the time of diagnosis. 
Surgical therapy included total thyroidectomy (72.1%) and limited or 
radical neck dissection (69.4%). Radioactive iodine (131I) was used to treat 
residual cancer and/or distant metastasis in 73.8% of the patients. 
External radiation therapy was used to treat locally advanced or recur- 
rent disease in 52.3% of the patients. 
Distant metastases and local recurrence were identified earlier in 
patients with follicular thyroid cancer whose surviva ! time and disease- 
free interval were significantly shorter (p < 0.001) than that of patients 
with papillary neoplasms. However, the survival and disease-free inter- 
vals were often very long in both papillary and follicular thyroid cancer 
deaths. 
Onset of differentiated thyroid cancer before the age of 40 years does 
not preclude serious sequelae and death. Since no known histopathologic 
features can consistently predict outcome, we continue to advocate 
aggressive treatment of all patients with differentiated thyroid cancer. 
Several factors have been associated with a poor prognosis in 
differentiated thyroid cancer including age (males > 40 yr, 
females > 50 yr), male sex, and tumor characteristics such as 
size (>1.5 cm), capsular and vascular invasion, extent, type, 
and grade [1-6]. No single microscopic or ultrastructural fea- 
ture has emerged as a reliable means of predicting a fatal 
outcome. Of these factors, age at initial diagnosis is considered 
to be the single most important indicator of eventual outcome 
[3]. The extent of thyroidectomy as a determinant of outcome, 
especially in patients under age 45 years, continues to be 
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debated among experienced thyroid surgeons, and remains an 
unsolved controversy. 
In 1964, Tollefsen reported 70 fatal cases of papillary cancer 
[1]. Other reports have added to Tollefsen's findings and have 
emphasized the often long periods of time observed from the 
time of initial diagnosis and treatment to the time of eventual 
recurrence and death [5, 6]. Series reporting only 10- to 15-year 
follow-ups are less meaningful since documented instances of 
recurrence occur 15-25 years following initial treatment and 
death may occur as long as 30 years following initial therapy. 
We review the 46-year experience at the University of 
Michigan, Ann Arbor,  Michigan, U.S.A.  in an effort to further 
define prognostic factors found in fatal differentiated thyroid 
cancer. 
M e t h o d s  
The Cancer Registry (Department of Medical Information, 
University of Michigan Hospitals) maintains a record of all 
patients with malignant neoplasms seen at this institution. The 
registry was searched for all patients with the diagnosis of 
differentiated papillary and/or follicular thyroid cancer seen 
between 1940 and 1986. Patients with medullary, anaplastic, 
Htirthle cell, and lymphomatous neoplasms of the thyroid were 
excluded. The registry was then searched to determine which 
patients were known to have died and the status of their thyroid 
neoplasm at death. The medical records of all deceased patients 
with thyroid cancer were reviewed by one or more of the 
authors. All data were recorded on a predetermined survey 
form that included demographic data, sex, age at diagnosis, 
type and duration of symptoms, tumor size, number and type of 
operations performed, uptake of  radioiodine, t r ea tment  with 
radioiodine, external radiation therapy or chemotherapy,  pres- 
ence of local or distant metastases at the time of diagnosis, 
interval between initial treatment and discovery of local or 
distant recurrence, length of follow-up, and cause of death. 
Copies of pertinent summaries, operative notes, pathology 
reports (including autopsy reports), clinic visits, and death 
certificates were reviewed. Only the pathologic reports of the 
University of Michigan Hospitals were accepted for determin- 
ing cell type. When the cause of death could not be determined 
from the medical record, telephone inquiry was made to obtain 
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Table 1. Distribution of thyroid neoplasms by sex and cell type. 
Follicular Papillary Total 
Men 23 (13.9%) 143 (86.1%) 166 
Women 140 (22.2%) 492 (77.8%) 632 
Total 163 635 798 (100%) 
information about the cause of death and status of the patient 's  
thyroid carcinoma at the time of death. Data were compiled and 
analyzed using a Statistical analysis program designed for large 
data bases (MIDAS, University of Michigan Computer Center). 
Results  
From 1940 to 1986, a total of 832 cases of differentiated thyroid 
cancer were recorded by the Cancer Registry at the University 
of Michigan Hospitals.  Thirty-four patients were found to have 
cancer at autoPsY or as an incidental finding during major head 
and neck surgery and were excluded from this report since they 
had not undergone treatment for primary thyroid cancer. Of the 
remaining 798 patients, the sex and thyroid cancer histology !s 
shown in Table 1. Of these 798 patients, 626 were alive at the 
end of 1986. Of the 172 who had died: 42 (24.4%) patients died 
from thyroid cancer, 14 (8.1%) died from concurrent disease 
with thyroid cancer present,  75 (43.6%) died with no thyroid 
cancer present; and 41 (23.8%) died with the status of their 
thyroid cancer unknown (Fig. 1). In the group in whom the 
thyroid cancer status was unknown, there were no cases of 
documented recurrence, distant metastasis, or active thyroid  
cancer at the time of the patients '  last follow-up visits. 
Death was caused by thyroid cancer in 5.3% of the patients. 
Thyroid cancer was present,  but not the cause of death in 1.8% 
(Fig. 2). All 14 of these patients had extensive local or meta- 
static thyroid cancer present at the time of death from other 
causes. No cancer was present in 9.4% of the patients; and 
5.1% of the patients died without records of their thyroid cancer 
status. 
Histology 
Twenty-eight (66.7%) neoplasms were classified as papillary, or 
follicular variant of papillary. Fourteen (33.3%) cancers were 
classified as follicular carcinoma, and contained no papillary 
changes. Although Htirthle cell changes were present in some 
tumors, there were no HOrthle cell tumors in this group. None 
of the 42 carcinomas showed anaplastic degeneration at the 
time of original diagnosis. 
Age and Sex 
The mean age at diagnosis of the 42 patients who died from 
thyroid cancer was 48.3 -+ 17.7 years (range, 6-77 yr). Patients 
dying from follicular cancer were equally divided among the 
sexes and were older at the time of diagnosis than their 
counterparts with papillary carcinoma [mean age, 57.1 -+ 12.3 
years (range, 40-77 yr) versus 43.8 -+ 18.5 years (range, 6-69 
yr)]. The age of onset was similar for males and females with 
follicular carcinoma: males, 56.6 years (range, 40-76 yr); fe- 























Fig. 1. Breakdown of deaths by category and percentage. 
I 
[ I 
42D.ths I t4Deaths 
FROM Thyroid wIm-I Thyroid 
Cancer I Cancer 











Fig. 2. Breakdown of deaths by category and percentage as compared to 
entire group of cases. 
patients who died of papillary cancer, 8 were male and 20 were 
female. The average ag e at diagnosis of the 8 males with 
papillary cancer was 50.9 years (range, 11-68 yr) and of the 20 
females was 41 years (range, 6-69 yr). 
Extent of Initial Cancer 
For 15 of 42 cases, size of tumor was noted in the pathologic or 
operative records (Table 2). These tumors were notable for both 
their large size and extrathyroidal extension. Local  invasion, 
palpable metastatic cervical lymph nodes, or both, were found 
in 25 (59.5%) patients. Initial metastases to lung (6 patients), 
bone (2 patients),  or other sites (1 patient) was seen in 9 (21.4%) 
patients. When categorized histologically, 16.0% of papillary 
and 41.7% of follicular cancers had initial distant metastasis. 
Surgical Therapy 
Table 2 lists the surgical procedures performed on the 42 
patients. A much higher percentage (78.5%) of the papillary 
cases had an initial or completion total thyroidectomy than the 
follicular cases (57.2%). Conversely, a higher percentage of the 
follicular cancer patients (42.9%) had no lymph node proce- 
dures performed than did the papillary patients (22.7%). Sixteen 
patients (38%) had a previous thyroid operation prior to their 
referral to our medical center. Thirty-three (78.6%) of the 42 
patients were referred to our medical center for therapy after a 
diagnosis of thyroid cancer had been established. The category, 
"o ther , "  includes such procedures as lymph node biopsy and 
tumor debulking. 
For the past 35 years, total thyroidectomy following intraop- 
erative frozen section to confirm presence of ma!ignancy has 
been performed for treatment of diffei'entiated thyroid neo- 
plasms. In patients referred after less than " to ta l "  thyroidec- 
tomy, completion thyroidectomy is done to facilitate the use of 
radioactive iodine and to remove anY residual thyroid neo- 
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Table 2. Mean tumor size and surgical therapy. 
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Mean tumor size (cm) 
4.7 • 4.4 • 3.6 4.9 x 4.1 • 3.7 4.5 x 4.9 • 3.6 
Type of operation All cases (%) Papillary (%) Follicular (%) 
Total thyroidectomy 51.2 57.1 42.9 
Completion thyroidectomy 20.9 21.4 14.3 
Total 72.1 78.5 57.2 
Subtotal thyroidectomy 20.9 14.3 35.7 
Other 7.0 7.1 7.1 
Lymph node sampling 30.6 27.3 35.7 
Modified radical neck dissection 22.2 27.3 14.3 
Radical neck dissection 13.9 18.2 7.1 
Regional lymph node dissection 2.8 4.5 0.0 
No lymph node dissection 30.6 22.7 42.9 
Table 3. 1311 therapy. 
All cases Papillary Follicular 
No. of patients treated 31 (73.8%) 18 (64.3%) 13 (92.9%) 
Total dose, (range) 326.1 mCi _+ 206, 302.5 mCi -+ 205, 370.3 mCi -+ 212, 
(91.9-966.0) (91.9-966.0) (91.9-805.9) 
No. of treatments, (range) 2.5 -+ 2.5 2.9 • 3.2 2.1 +- 1.0 
(1-11) ( l - l l )  (1-4) 
plasm, if possible. The main objective in the operating room 
was primary surgical control of the thyroid cancer. 
Radioactive Iodine External Radiation Therapy and 
Chemotherapy 
Radioactive 131I has been used for the treatment of regional and 
distant spread of differentiated thyroid cancer in our medical 
center since 1947. All but 1 patient with follicular cancer and 18 
of 28 papillary cancer patients received 131I therapy (Table 3). 
Those not treated had either no uptake of m I  by their metas- 
tasis or the therapy was not available. 
Radiation therapy was used in 22 (52.3%) patients to control 
locally advanced Or recurrent disease. Only 3 patients received 
chemotherapy during the final stages of their disease. 
Recurrent Disease 
Table 4 lists the data on the development of distant metastasis 
and regional recurrence. The data include those patients who 
presented with distant metastasis and those whose local/re- 
gional disease could not be cured. 
What is highly significant (p < 0.001) is the difference in time 
of onset of both distant metastasis and regional recurrence of 
follicular cancer as compared to papillary. Follicular cancer 
was more rapidly progressive and difficult to manage: Distant 
metastases developed nearly 3 times faster ( 3 3 . 5 -  + 43 months 
versus 87.5 -+ 80.8 months) in those with papillary tumors and 
regional recurrences, 6 times faster (11.4 -+ 9.6 months versus 
68.7 -+ 60.8 months). Papillary cancer typically metastasized to 
the lung (48.0%) while follicular cancer was usually found in 
multiple sites (46.2%). 
The long time between initial diagnosis of papillary cancer 
and development of metastases was notable: up to 25 years (300 
months) for distant metastases, and up to 17 years (204 months) 
Table 4. Development of distant metastasis. 
All cases Papillary Follicular 
Incidence (%) 86.8 88.0 84.6 
Site of distant metastasis (%) 
Lung 42.1 48.0 30.8 
Bone 2.6 0.0 7.7 
Multiple 34.2 28.0 46.2 
Other 7.9 12.0 0.0 
Time of onset (too), (range) 68.3 -+ 73.7 87.5 +_ 80.8 33.5 _+ 43 
(0-300) (0-300) (0-132) 
Regional recurrence 
Incidence (%) 
Time of onset (mo), (range) 
66.7 70.8 58.3 
50.5 -+ 56.9 68.7 -+ 60.8 11.4 +- 9.6 
(0-204) (0-204) (2-24) 
for regional recurrence. Illustrative cases deserve special re- 
view. 
Case 1. A 62-year-old woman presented in 1953 with a 12- 
month history of a progressively enlarging goiter. She under- 
went subtotal thyroidectomy for papillary carcinoma, and 11 
years later developed a cervical metastasis which was treated 
by excision of the involved nodes, completion total thyroidec- 
tomy, and 194.0 mCi of 131I. Fourteen years later (25 years after 
the initial diagnosis and treatment), she developed pulmonary 
metastases which did not take up 1311. She died of widespread 
pulmonary metastases 1 year later at age 88 (31 years after the 
initial diagnosis). 
Case 2. A 30-year-old woman presented in 1947 with a 1-month 
history of a progressively enlarging neck mass. She was treated 
with a "near- total"  thyroidectomy for her papillary thyroid 
cancer. Seventeen years later, the patient developed a recur- 
rence in the neck which was treated by a radical neck dissec- 
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Table 5. Survival and disease-free interval. 
All cases Papillary Follicular 
Survival (yr), (range) 10.5 -+ 9.0 13.0 -+ 9.7 5.5 -+ 4.6 
(1 mo-31 yr) (3 mo-31 yr) (i mo-i7 yr) 
Disease-free (yr), (range) 5.3 -+ 6.7 7.2 -+ 7.2 i.5 -+ 2.9 
(0 mo-24 yr) (0 mo-24 yr) (0 mo-11 yr) 
tion. Postoperative 1311 scanning demonstrated no uptake. 
Therefore, no 1311 therapy was given. Fourteen years later, at 
age 61, the patient died of generalized carcinomatosis, 31 years 
after initial diagnosis and treatment.  
Survival and Disease-Free Interval 
Table 5 lists the mean survival and disease-free intervals for the 
42 patients. The difference in mean survival between patients 
with papillary and follicular cancer is highly significant (p < 
0.001) and demonstrates the different biological behavior of 
these two cancers. Follicular cancer is more rapidly fatal, 
although the disease-flee interval can demonstrate significant 
variation and very long periods may elapse (up to 24 years) 
prior to development of recurrent disease. 
The next several cases illustrate the varied and prolonged 
course of  many patients with ultimately fatal thyroid cancer, 
and show the sometimes fatal nature of thyroid cancer in 
patients under age 45. 
Case 3. A 21-year-old woman presented with a 4-month history 
of multinodular goiter in 1962. She underwent total thyroidec- 
tomy in an outside hospital for papillary cancer, and 1 month 
later had a right radical neck dissection for cervical metastasis. 
Within 4 months she developed left-sided cervical metastasis 
and was treated with a left radical neck dissection and external 
radiation therapy. We first saw her 25 months later for treat- 
ment of pulmonary metastases and administered 480 mCi of 1311 
in 4 doses over the following 8 years. Her pulmonary metasta- 
ses stabilized, but never cleared, and she died of cancer at age 
32, nearly 11.5 years after the initial diagnosis. 
Case 4. A 47-year-old male presented in 1964 with a 12-month 
history of a progressively enlarging right neck mass. He was 
treated for papillary thyroid cancer at an outside hospital with a 
right thyroid lobectomy. Eight years later he was referred to our 
medical center for a recurrent right neck mass. At operation, we 
found an extensive tumor with invasion of the brachial plexus. 
Completion total thyroidectomy and a modified radical neck 
dissection were performed. Postoperative J31I scintiscanning 
demonstrated both cervical and pulmonary uptake. He was 
subsequently treated with 966.0 mCi of 131I in 5 doses over a 
9-year period. His pulmonary metastases stabilized, but never 
cleared. He died from his pulmonary metastases at age 65, 18 
years after his initial diagnosis. 
Case 5. A 6-year-old female received thymic irradiation during 
the first year  of life in 1948. By age 6 she had developed a left 
thyroid mass with pulmonary metastases. She was treated at an 
outside hospital with a left thyroid lobectomy followed by 3,000 
rads of external radiation therapy to the neck. She was subse- 
quently referred to the University of Michigan for completion 
total thyroidectomy and received 400 mCi of 131I in 11 doses 
over a 6-year period with complete clearing of her pulmonary 
metastases for the next 20 years. Her pulmonary metastases 
then recurred and she was treated with chemotherapy. She died 
at age 36, 30 years after her initial diagnosis and treatment. 
Discussion 
The report by Tollefsen et al. in 1964 focused attention on the 
general relationship between inadequate treatment of papillary 
cancer and subsequent death [1]. Nine (12.8%) of their reported 
70 deaths had pulmonary metastases when initially seen. The 
average age at diagnosis of the fatal cases was 52 years. Twenty 
(29%) of the 70 patients had tumors larger than 5 cm in 
diameter. The cause of death was local recurrence in the neck 
in 40%, pulmonary metastases in 31%, bone metastases in 10%, 
and metastases to other sites in 19% of patients. Thirty (43%) of 
their patients were considered incurable when initially seen and 
uncontrolled locally recurrent cancer in the neck was the most 
common cause of death. 
Subsequently, in 1973, Tollefsen et al. reported on their initial 
experience with follicular carcinoma of the thyroid [2]. Follic- 
ular cancer was found in older patients when compared to 
papillary cancer, and the incidence of initial distant metastasis 
was 9% and subsequent distant metastasis was 25%. There was 
only a 70% 5-year survival rate. Only in cases of distant 
metastases did they advocate total thyroidectomy in order that 
131I could be used. 
Cady et al. consider the age of the patient to be the key factor 
in survival from differentiated thyroid carcinoma and noted that 
85% of deaths in their series occurred in patients older than 40 
years of age [3]. "High-r isk"  patients were men over 40 and 
women over 50 years. All other patients were considered to be 
at " low-risk" for eventual death from thyroid carcinoma. 
In 1981, Mazzaferri  and Young reported on a 10-year fol- 
low-up of 576 papillary cancer patients [4]. The average age of 
their patients was 32.4 years (range, 6-75 yr). Mortality was nil 
in patients under age 30 years at initial diagnosis, or when the 
primary cancer was under 1.5 cm in diameter, even though 4 
(0.7%) had pulmonary metastasis at diagnosis. Local tumor 
invasion and cervical lymph node metastases had higher recur- 
rence rates and markedly increased mortality. The time from 
initial treatment to recurrence averaged 55.6 -+ 9.4 months, and 
the highest recurrence rate was in patients receiving external 
radiation therapy and thyroid hormone replacement. Most 
importantly, the group of 310 patients who had an initial total 
thyroidectomy had significantly fewer recurrences (p < 0.01) 
than those treated initially by subtotal thyroidectomy. 
In the last 2 years, 2 important series have been published [5, 
6]. Tubiana and co-workers reported 546 differentiated thyroid 
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cancers [5]. He concluded that overall survival at 10 years is 
insufficient for assessing the efficacy of initial treatment because 
late relapses were frequent and long delays often occurred 
between relapse and death. In 12 of 49 relapsing patients, the 
recurrences occurred more than 20 years after the first treat- 
ment. Mortality increased sharply at age 45 and was higher in 
patients with moderately differentiated follicular cancers. 
These data show that when follow-up is sufficiently long, 
relapses are more frequent than previously reported and death 
may occur 20-35 years after initial treatment. While the possi- 
bility of local recurrence or distant metastases decrease with 
time, it never disappears and they conclude that patients need 
lifelong follow-up. 
McConahey et al. reported retrospectively on 859 patients 
with papillary thyroid cancer treated at the Mayo Clinic from 
1946 to 1970 [6]. Their maximum follow-up was 39 years. 
Fifty-six (6.5%) patients died from papillary cancer. Death was 
associated with age greater than 50 years, male sex, tumor size, 
tumor grade, initial extent of disease, and the absence of 
Hashimoto's disease. Mean time of death following operative 
treatment was 8.2 years (range, 1 mo-31 yr). With the appear- 
ance of a new distant metastatic lesion, 36% of patients died 
within 5 years and 65% within 20 years. There was a highly 
significant correlation (p < 0.001) between tumors 4 cm or 
larger in diameter and the development of either local recur- 
rence or distant metastases. The risk of death increased with 
increased tumor size. 
Our data are consistent with reports of similar large numbers 
of patients followed over long periods of time. Our patients who 
died had large, locally extensive tumors, frequently with initial 
distant metastases. Fifteen of our 42 deaths were in males 
(35.7%), while males made up 20.8% of the original 798 cases. 
While age remains an important prognostic factor in differ- 
entiated thyroid cancer, our data clearly demonstrates that 
death can occur in those aged 45 years and younger. Females in 
our series who died from papillary cancer had an average age of 
41 years at initial diagnosis. Fully one-third of our 42 deaths 
from thyroid cancer were in patients who were 45 years old or 
younger, when their diagnosis was made. Younger patients are 
not immune to serious sequelae and death from thyroid cancer 
and they should be treated as aggressively as patients older than 
45 years of age. 
What is striking in our series of deaths, and similar to the 
report by Tubiana et al. [5], are the variably long times seen in 
the development of local recurrences and distant metastases (up 
to 25 years after initial treatment). Therefore, all patients with 
differentiated thyroid cancers require lifelong follow-up. Re- 
ports on the results of treatment for thyroid cancer need 
follow-ups of at least 20 years if the series are to be meaningful. 
In our series, follicular cancer was very aggressive. These 
patients had significantly shorter survivals and disease-free 
intervals (p < 0.001). This experience is similar to others [2, 3, 
5] and demonstrates that papillary and follicular cancers are not 
considered as equivalent tumors with respect to prognosis. 
The overall mortality from differentiated thyroid cancer in 
our review is 5.3% (42/798). If we assume that all of the 14 
patients who died of their concurrent disease would have died 
from their thyroid cancers, then the cumulative mortality rate 
would be 7.1% (56/798). These results are similar to other 
reported series [2-6], and correct for the fact that the majority 
of thyroid cancer cases referred to our medical center have 
relatively advanced disease. 
A consistent policy of total thyroidectomy for the treatment 
of all thyroid cancers greater than 1 cm has been followed at our 
institution since 1959. In our experience, total thyroidectomy 
plus appropriate cervical lymph node dissection is important 
not only to adequately control the cancer in the neck, but to 
allow the use of 131I for the treatment of distant metastases. We 
continue to advocate such an aggressive approach until a 
biologic marker is found that will allow the identification of 
those patients whose disease is more aggressive and ultimately 
fatal. 
R6sum6 
Entre 1940 et 1986, 798 patients au total ont 6t6 trait~s pour un 
cancer diff6renci6 de la thyro~de. Cent-soixant-douze patients 
sont morts par la suite: 42 (24.4%) de leur cancer, 14 (8.1%) 
d 'une autre cause alors que des signes d 'extension du cancer 
6taient pr6sents, 75 (43.6%) d 'une autre cause sans signe de 
cancer, et 41 (23.8%) sans qu'on ait pu connaitre le stade du 
cancer. 
Des 42 patients morts de leur cancer, il y avait 15 hommes et 
27 femmes. L'fige moyen au moment du diagnostic 6tait de 48.3 
-+ 17.7 ans: un tiers des patients avait 45 ans ou moins au 
moment du diagnostic. Les tumeurs primitives avaient plus de 
4 cm et 59.5% des patients pr6sentaient un envahissement local 
et/ou une m6tastase cervicale. Les m6tastases ~ distance ont 6t6 
ddtect6es chez 9 (21.4%) patients au moment du diagnostic. 
Une thyroidectomie totale a 6t6 effectu6e chez 72.1% des 
patients, associ6e /~ un curage cervical limit6 ou radical chez 
69.4% des patients. Chez 73.8% des patients on a trait6 le tissu 
cancdreux r6siduel et/ou des m6tastases ~t distance par de 1'I 
131. La radioth6rapie a 6t6 utilis6e pour traiter les patients 
prdsentant une extension importante ou une rdcidive chez 
52.3% des patients. 
Des m6tastases g distance et des r6cidives ont 6t6 identifi6es 
prdcocement chez les patients ayant un cancer folliculaire. 
Dans ce groupe de patients, la survie et l 'intervalle de temps 
sans maladie dtaient significativement plus courts (p < 0.001) 
que chez les patients ayant un cancer papillaire. I1 faut cepend- 
ant noter que la survie et l 'intervalle de temps sans maladie 
6talent tr~s longs dans les 2 groupes de patients. 
La d6couverte d 'un  cancer diff~renci6 de la thyro~de avant 
l'fige de 40 ans n 'est  pas un facteur pronostique particulier. 
Puisqu'il n 'y  pas de facteur histologique permettant de pr6voir 
l'dvolution, nous continuons de pr6coniser un traitement agres- 
sif chez tout patient prdsentant un cancer diffdrenci6 de la 
thyroide. 
Resumen 
En el perfodo 1940-1986, un total de 798 pacientes recibieron 
tratamiento para carcinoma tiroideo; 172 murieron en el curso 
del seguimiento: 42 (24.4%) por cfincer tiroideo, 14 (8.1%) por 
otras causas pero con presencia de extenso cfincer tiroideo, 75 
(43.6%) libres de cfincer tiroideo, y 41 (23.8%) con estado 
desconocido en cuanto al cfincer tiroideo. 
De 42 pacientes que murieron por c~incer tiroideo, 15 eran 
hombres y 27, mujeres. Su edad promedio en el momento del 
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diagndstico rue 48.3 -+ 17.7 afios, con una tercera parte de los 
pacientes de 45 afios o menos. Sus tumores primarios eran de 
tamafio grande (>4 cm) y 59.5% presentaban invasi6n local y/o 
mefftstasis cervicales. Se encontraron metgtstasis distantes en 9 
(21.4%) en el momento del diagn6stico. 
La terapia quirtirgica incluy6 tiroidectomia total (72.1%) y 
disecci6n radical o limitada del cuello (69.4%); 73.8% de los 
pacientes recibieron yodo radioactivo (~3~I) como tratamiento 
de cilncer residual y/o mefftstasis distantes. La radioterapia 
externa fue utilizada en el manejo de enfermedad local avanza- 
da o enfermedad recurrente en 52.3% de los pacientes. 
Metilstasis distantes y recurrencia local fueron identificadas 
m~is tempranamente en pacientes con cilncer folicular cuya 
supervivencia y lapso de tiempo libre de enfermedad fueron 
significativamente mils cortos (p < 0.001) que los de los 
pacientes con neoplasmas papilares. Sin embargo, las superviv- 
encias y los lapsos libres de enfermedad con frecuencia 
aparecieron muy prolongados tanto en los muertos por cilncer 
papilar como en aquellos muertos por c incer  folicular. 
La aparici6n del c incer  diferenciado de la glindula tiroides 
antes de los 40 afios de edad no implica libertad de secuelas 
graves o de mortalidad. Puesto que se conocen caracteristicas 
histopatol6gicas que puedan predecir en forma consistente el 
prondstico, nosotros continuamos preconizando tratamiento 
agresivo en todo paciente con c~incer diferenciado de tiroides. 
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Invited Commentary 
Oliver  H. Beahrs ,  M.D.  
Department of Surgery, Mayo Clinic, Rochester, Minnesota, U.S.A. 
This article adds further information regarding the biological 
behavior of the well-differentiated carcinomas of the thyroid 
gland. It also adds data that the pure papillary lesions including 
those with mixed papillary and follicular histologic components 
behave differently than the undifferentiated lesions. The latter 
are more rapidly progressive, spread to distant sites, and are 
more difficult to manage. Likewise, there is a higher death rate 
with the undifferentiated cancers. The papillary cancers typi- 
cally spread to the lungs while the follicular cancer spreads to 
multiple distant sites and more frequently so than the papillary 
lesions. Follicular tumors have lymph node involvement less 
frequently than papillary lesions. Both types have a long life 
history. 
Follicular cancers are generally seen in patients 1 decade 
older than patients with papillary lesions. The use of 131I is more 
frequently of value in the management of follicular lesions than 
papillary tumors. 
From the factors mentioned above and recorded in this 
article, it should be clear that there is a difference in the 
histological pattern of papillary adenocarcinoma and pure fol- 
licular adenocarcinoma and that the biological behavior of the 2 
lesions are somewhat different and data regarding each type 
should be reported separately. This is recognized and done in 
this article, but data is also reported regarding the combined 
series, which is of no value and leads to some confusion in 
reporting information about these 2 somewhat different well- 
differentiated cancers of the thyroid gland. It would be best not 
to combine data on both. 
It is acknowledged that both types of well-differentiated 
carcinoma grow slowly and it is necessary to observe patients 
with these lesions over long periods of time to observe results of 
treatment and prognosis. It is frequently stated that the tumors 
in the older age group (40-45 years of age) are more serious. 
Might it be that many of these tumors are more advanced and 
first become apparent later in life--thus, increased mortality in 
patients 40:-45 years of age or older? Even the illustrative case 
given in this article substantiates this fact: the onset of tumor at 
6 years of age and death from the tumor at 36 (it could have 
been 40 years of age). 
The authors advocate total thyroidectomy for all patients 
with differentiated cancer of the thyroid. Certainly, this ap- 
proach is justified when secondary surgery is carried ou t - -  
which was true in many of their cases or in advanced lesions. 
However, their series of cases, 42 of 798, represent only 
one-half of 1% of the total series. In the authors hands, the 
morbidity of total thyroidectomy is undoubtedly very low, but 
this would not be the experience of surgeons in general. The 
extent of the surgical procedure should be tailored to the extent 
of the primary lesions. Woolner [1] has reported 244 cancers of 
the thyroid 1 V2 cm or less in diameter, about 40% with regional 
nodule spread followed 40 years without a single death from 
thyroid cancer, essentially, all treated by less than total thy- 
roidectomy. The emphasis should be on selective extent of 
thyroidectomy, depending on gross findings at the time of 
surgery. 
Lastly, a scheme of staging of cancer of the thyroid has not 
been generally accepted: For this reason, all data reported in 
this and other articles is of limited value. The American Joint 
Committee on Cancer (AJCC) along with the TNM Committee 
